Navigation Links
3SBio Inc. Files for SFDA Approval of NuLeusin
Date:11/10/2008

SHENYANG, China, Nov. 10 /Xinhua-PRNewswire/ -- 3SBio Inc. (Nasdaq: SSRX), a leading biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China, today announced that it has filed with the Chinese State Food and Drug Administration (SFDA) for approval of NuLeusin for the treatment of late stage metastatic renal cell carcinoma. If approved, NuLeusin is expected to be the only treatment of this kind available in China.

NuLeusin, 3SBio's second-generation IL-2, is a genetically modified form of IL-2 possessing improved biochemical properties over naturally occurring IL-2. Clinical trials examined the safety and efficacy of two treatment cycles of subcutaneous injections of NuLeusin. During each six-week treatment cycle, patients were given daily doses of 7MIU/square meter in the induction phase and daily doses of 3.5MIU/square meter in the maintenance phase. The results showed an overall efficacy (Complete Response +Partial Response) of 12.73% and a disease control rate (Complete Response+ Partial Response+ Stable Disease) of 60%. Compared to Chiron's Proleukin, a treatment available in the United States, which is believed to be the only similar product on the market today, Nuleusin demonstrated similar levels of efficacy with a much lower dosage. More importantly, NuLeusin showed an improved safety and tolerability profile in patients who participated in the Phase III study.

"Today's submission comes only a little over one month following our submission for high dosage EPIAO and once again demonstrates our outstanding research and development capabilities and our strong ability to execute on our business plan," stated Dr. Jing Lou, Chief Executive Officer of 3SBio. "NuLeusin was developed to provide a new immunotherapy regimen for oncologists to treat patients with late stage metastatic renal cell carcinoma. Upon approval, we believe many patients who have exhausted their treatment options will benefit from this new alternative. In addition, Nuleusin is expected to further expand 3SBio's existing presence in the rapidly growing oncology market in China."

About the Phase III Study

The Phase III study was a multi-center, open label, single arm study carried out in nine first-tier hospitals in Beijing. The study enrolled 75 patients with post surgery renal cell carcinoma metastasis into two six-week treatment cycles, with a two-week break between each cycle. Patients were given subcutaneous injections of 3.5MIU/ square meter NuLeusin every twelve hours, twice a day, for five consecutive days in the first week of each treatment cycle during the induction phase. From the second week onward, during the maintenance phase, patients received daily subcutaneous injections of 3.5MIU/square meter NuLeusin for five consecutive days each week. The maximum number of treatment cycles patients could receive was three. The clinical endpoint was assessed using computerized tomography scan image of tumor response.

The results of Phase III study demonstrated NuLeusin to be an effective treatment for metastatic renal cell carcinoma with improved safety and tolerability, with an overall efficacy of 12.73% and a disease control rate of 60% (per protocol site). The possible causes for the difference in efficacy compared to Proleukin could be variations in patient race, injection dosage, and route of administration and treatment time. The most common adverse effect related to NuLeusin was low fever and injection site reactions.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at: http://www.3sbio.com.

Safe Harbor Statement

Statements in this release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management's current expectations, and actual results could differ materially. Among the factors that could cause 3SBio's actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; the completion of 3SBio's ongoing clinical trials as planned; receipt and timing of regulatory approvals for 3SBio's new products and uses; 3SBio's ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio's financial results, please refer to the company's filings with the Securities and Exchange Commission at http://www.sec.gov . 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

For more information, please contact:

Investor Contact:

David Chen, COO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations (US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Investor Relations (HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Media Contact:

Jason Marshall

Taylor Rafferty

Tel: +1-212-889-4350


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
2. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
3. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
4. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
5. 3SBio Inc. Announces Results of Annual General Meeting
6. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. 3SBio Inc. to Hold Annual General Meeting
8. 3SBio Inc. Announces Second Quarter 2008 Results
9. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
10. 3SBio Inc. to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
11. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... York , April 29, 2016 ... published by Transparency Market Research "Separation Systems for ... Share, Growth, Trends, and Forecast 2015 - 2023", ... valued at US$ 10,665.5 Mn in 2014 and ... 6.8% from 2015 to 2023 to reach US$ ...
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... Inc., will hold an open house for regional manufacturers at its Maple Grove, ... from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers ...
(Date:4/27/2016)... VANCOUVER, British Columbia , April 27, 2016 ... "Gesellschaft" oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... sie im Anschluss an ihre Pressemitteilung vom 13. ... Inc. erhalten hat, ihre Finanzen um zusätzliche 200.000.000 ... auf 4.000.000 Kanadische Dollar zu bringen. Davon wurden ...
Breaking Biology Technology:
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):